Skip to main content
Premium Trial:

Request an Annual Quote

Devgen Creates C. elegans RNA Interference Library

NEW YORK, Feb. 22 - Belgian functional genomics company Devgen on Friday said it has created a complete C. elegans RNA interference library.

The library is genome-wide, including complexes that can suppress the activity of each of the 19,000 C. elegans genes. Devgen plans to use the library in drug-target identification and functional validation.


RNAi is a form of post-transcriptional gene silencing that works by targeting and cleaving endogenous mRNA.


Devgen, based in Ghent, uses C. elegans as a model for target and drug discovery. It uses RNAi knockdown technology in the worm to evaluate gene function, and combines that technique with a comparative-genomics approach to understand human homologues of disease pathways.


The company, which employs about 90 people, is privately held. It has partnerships with Princeton, NJ-based  FMC Corp. for new pesticide discovery, and with Metabolex for diabetes research.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.